Celexor Bio

Celexor Bio, co-founded by Inmagene Biologics and venture capital firm Aditum Bio, is a novel drug development company that leverages the mechanism of clearing pathological cells to treat autoimmune and inflammatory diseases. Celexor Bio was established based on Inmagene's IMG-018 product, which is a monoclonal antibody targeting Immunoglobulin-like Transcript 7 (ILT7) and has a potent ability to deplete pDCs.